NCCN awards grants to five young investigators

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Rebecca Arend
Yin Cao
Tim Luetkens
Edwin Manuel
Cecilia Yeung

The NCCN Foundation has announced five recipients for this year’s Young Investigator Awards. The grantees come from National Comprehensive Cancer Network Member Institutions, and will each receive up to $150,000 in funding over a two-year period.

This marks the eighth year for the NCCN Foundation Young Investigator Awards supporting career development for innovative cancer researchers.

The 2018 awardees are:

Rebecca Arend, University of Alabama at Birmingham Comprehensive Cancer Center

The Role of TGF-β in Immune Suppression in Suboptimally Debulked Ovarian Cancer Patients

Yin Cao, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Disparities in Young-Onset Colorectal Cancer Survival According to Patient, Treatment, and Tumor Molecular Characteristics

Tim Luetkens, Huntsman Cancer Institute at the University of Utah

CD229 Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma

Edwin Manuel, City of Hope Comprehensive Cancer Center

Altering the Local Immune Landscape in Lung Cancer to Improve Anti-PD-1 Therapy

Cecilia Yeung, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Optimization of a Rapid Point of Care Device for Acute Promyelocytic Leukemia Diagnosis and Therapy Guidance

These five awardees were selected out of a pool of 48 applicants nominated from across the 27 NCCN member institutions. The NCCN Oncology Research Program will manage and oversee the projects for the next two years. The awardees will then present the results from their research at the NCCN 25th Annual Conference in 2020.

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login